The main purpose of this legislation is to extend and improve the Accelerating Access to Critical Therapies for ALS Act, which focuses on enhancing research and access to treatments for amyotrophic lateral sclerosis (ALS). The Act has been reauthorized to remain in effect until the end of fiscal year 2031, ensuring continued support for ALS research and treatment initiatives. Key provisions of the legislation include the extension of grant funding for ALS research, which will now be available until 2031.